Evidence map›Paper›PMID 29438360›Full record

ArticleBritish journal of cancer2018

An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.

A Linton, Y Y Cheng, K Griggs, L Schedlich, M B Kirschner, S Gattani, S Srikaran, S Chuan-Hao Kao, B C McCaughan, S Klebe and 2 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Translational cancer research · 2024
    Article
  2. Article
  3. Review
  4. Identification ofTranslational cancer research · 2021
    Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

A LintonAsbestos Diseases Research Institute (ADRI), University of Sydney, Concord, NSW 2139, Australia.
Y Y ChengAsbestos Diseases Research Institute (ADRI), University of Sydney, Concord, NSW 2139, Australia.
K GriggsDepartment of Anatomical Pathology, Flinders Medical Centre, Bedford, SA, Australia.
L SchedlichAsbestos Diseases Research Institute (ADRI), University of Sydney, Concord, NSW 2139, Australia.
M B KirschnerAsbestos Diseases Research Institute (ADRI), University of Sydney, Concord, NSW 2139, Australia.
S GattaniAsbestos Diseases Research Institute (ADRI), University of Sydney, Concord, NSW 2139, Australia.
S SrikaranAsbestos Diseases Research Institute (ADRI), University of Sydney, Concord, NSW 2139, Australia.
S Chuan-Hao KaoAsbestos Diseases Research Institute (ADRI), University of Sydney, Concord, NSW 2139, Australia.
B C McCaughanCardiothoracic Surgical Unit, Royal Prince Alfred Hospital; The Baird Institute and Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
S KlebeDepartment of Anatomical Pathology, Flinders Medical Centre, Bedford, SA, Australia.
N van ZandwijkAsbestos Diseases Research Institute (ADRI), University of Sydney, Concord, NSW 2139, Australia.
G ReidAsbestos Diseases Research Institute (ADRI), University of Sydney, Concord, NSW 2139, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This corrects the article DOI: 10.1038/bjc.2017.85.

Identifiers

PMID29438360
PMCPMC5908673

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.